Cel-Sci Corp (CVM) 0.69 $CVM
Investors look to Lighten Up on Shares of CEL-SCI, Shares Down 20.6% (CVM)
Comtex SmarTrend(R) - Tue Oct 21, 10:13AM CDT
CEL-SCI (AMEX:CVM) is one of today's worst performing penny stocks, down 20.6% to $0.68 on 7.0x average daily volume. Thus far today, CEL-SCI has traded 2.0 million shares, vs. average volume of 285,000 shares per day. The stock has underperformed the Dow (-20.6% to the Dow's 0.6%) and underperformed the S&P 500 (-20.6% to the S&P's 1.2%) during today's trading.
CVM: 0.69 (+0.02)
CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering
Business Wire - Tue Oct 21, 8:42AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, has agreed to sell common stock and warrants in a registered direct offering to European investors at a combined price of $0.76 for aggregate gross proceeds of a little over $1 million. For every four shares sold, we will issue to investors in this offering one warrant to purchase a share of common stock. The warrants are immediately exercisable, expire October 11, 2018, have an exercise price of $1.25 and trade on the NYSE MKT under the symbol "CVM WS". The offering is expected to close on or about October 24, 2014, subject to the satisfaction of customary closing conditions.
CVM: 0.69 (+0.02)
CEL-SCI Corporation Prices $6 Million Public Offering of Common Stock and Warrants
Business Wire - Tue Oct 21, 8:15AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has priced a "best efforts" underwritten public offering of common stock and warrants at a combined price of $0.76 for aggregate gross proceeds of $6 million, prior to deducting underwriting commissions and offering expenses and excluding the exercise of any warrants. For every four shares sold, we will issue to investors in this offering one warrant to purchase a share of common stock. The warrants are immediately exercisable, expire October 11, 2018, have an exercise price of $1.25 and trade on the NYSE MKT under the symbol "CVM WS". The offering is expected to close on or about October 24, 2014, subject to the satisfaction of customary closing conditions.
CVM: 0.69 (+0.02)
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants
Business Wire - Mon Oct 20, 3:30PM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it intends to offer and sell common stock and warrants in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed.
CVM: 0.69 (+0.02)
Warts Therapeutics Pipeline Review 2014
M2 - Mon Oct 13, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wc94mt/warts_pipeline) has announced the addition of the "Warts - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Helix BioPharma Corp. - CEL-SCI Corporation - NanoViricides, Inc. - 3M Drug Delivery Systems - G&E Herbal Biotechnology Co., Ltd. - Anaconda Pharma - Foamix Ltd. - BioMAS Ltd. - ViroStatics, srl - Cutanea Life Sciences - Burke Pharmaceuticals, LLC - Agilvax, Inc. - Nielsen Biosciences, Inc. Drug Profiles - interferon alpha-2b (recombinant) - AS-101 - SRT-100 - AP-611074 - Candida Albicans Antigen - (digoxin furosemide) - Leukocyte Interleukin - A-101 - BURKE-201 - AX-03 - HerpeCide-I - imiquimod - 854-A - PP-210 - Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts For more information visit http://www.researchandmarkets.com/research/wc...s_pipeline
CVM: 0.69 (+0.02), NNVC: 3.44 (+0.04)
CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial
Business Wire - Fri Oct 03, 8:15AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of September the Company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection).
CVM: 0.69 (+0.02)
Coverage Initiation Report Focuses on CEL-SCI Corporation
Marketwire - Wed Oct 01, 10:33AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) is the subject of an in-depth initiation coverage report by Acceleron Equity Research.
CVM: 0.69 (+0.02)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Wed Oct 01, 6:00AM CDT
hen a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
CVM: 0.69 (+0.02), PLUG: 4.30 (+0.01), NYNY: 6.51 (+0.17), MERU: 3.94 (+0.01)
CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients
Business Wire - Mon Sep 29, 7:00AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced the first volunteer patient has been enrolled and administered Multikine* (Leukocyte Interleukin, Injection) in a Institutional Review Board approved Phase I Clinical Trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women at the Naval Medical Center San Diego (NMCSD). The purpose of this dose escalation study is to evaluate the safety and impact of Multikine as a treatment of Human Papilloma Virus associated peri-anal warts and assess the effect on anal intraepithelial dysplasia (AIN) in HIV/HPV co-infected men and women.
CVM: 0.69 (+0.02)
Hot Stock: CEL-SCI, Shares Drop 5.5% (CVM)
Comtex SmarTrend(R) - Tue Sep 23, 11:36AM CDT
CEL-SCI (AMEX:CVM) is one of today's worst performing penny stocks, down 5.5% to $0.81 on 1.1x average daily volume. CEL-SCI has traded 263,000 shares thus far today, vs. average volume of 234,000 shares per day. The stock has underperformed the Dow (-4.9% to the Dow's -0.3%) and underperformed the S&P 500 (-4.9% to the S&P's -0.3%) during today's trading.
CVM: 0.69 (+0.02)
Valuation Analysis for CEL-SCI
ACCESSWIRE - Thu Sep 11, 5:18AM CDT
Los Angeles, CA / September 11, 2014 / On Wednesday, CEL-SCI Corporation (NYSEMKT: CVM) made public the fact that the respected University of Minnesota's Masonic Cancer Center has become part of the company's Phase III head and neck cancer clinical trial. This is the 7th clinical site in the U.S. to join CEL-SCI's late stage study for its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection).
CVM: 0.69 (+0.02)
University of Minnesota Masonic Cancer Center Joins CEL-SCI's Phase III Head & Neck Cancer Trial
Business Wire - Wed Sep 10, 7:45AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that the University of Minnesota's Masonic Cancer Center has becomes the 7th clinical site in the U.S. to join its Phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection).
CVM: 0.69 (+0.02)
Smallpox Therapeutics Pipeline Review Report 2014 - 15 Companies & 16 Drug Profiles
M2 - Wed Sep 10, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdcds3/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - Conkwest, Inc. - Inhibikase Therapeutics, Inc. - Polyrizon Ltd. Drug Profiles - smallpox vaccine [Modified Vaccinia Ankara - Bavarian Nordic Virus] - CJ-50300 - brincidofovir - Sym-002 - cidofovir - CEL-1000 - tecovirimat - DNA Vaccine for Smallpox - Smallpox Vaccine - CST-102 - DNA Vaccine for Smallpox - TPIV-300 - imatinib mesylate - Monoclonal Antibody for Infectious Disease - PL-801 - Smallpox Vaccine For more information visit http://www.researchandmarkets.com/research/hdcds3/smallpox
MGNX: 19.69 (+0.41), CMRX: 32.06 (+1.45), CVM: 0.69 (+0.02), SIGA: 1.39 (-0.03)
CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial
Business Wire - Wed Sep 03, 7:01AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced that it enrolled 20 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) during August 2014. This brings the total study enrollment to 252 patients.
CVM: 0.69 (+0.02)
CEL-SCI Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial into Centre Hospitalier Universitaire de Quebec in Canada
Business Wire - Tue Aug 19, 7:01AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has added Centre Hospitalier Universitaire de Quebec (CHUQ)'s L'Hotel Dieu de Quebec to its growing number of clinical sites in North America. CHUQ is a network of three teaching hospitals affiliated with the medical school of Universite Laval and several specialized institutions in Quebec City. CEL-SCI plans to activate additional clinical sites for accelerated patient enrollment in Canada.
CVM: 0.69 (+0.02)
Potential Payoffs Spur Big Board Biotech Action
ACCESSWIRE - Tue Aug 12, 2:03PM CDT
Los Angeles, CA / ACCESSWIRE / August 12, 2014 / Speculators were pushing certain big board biotechs higher as they placed their bets on potentially big future payoffs.
BCRX: 12.19 (+0.49), CVM: 0.69 (+0.02), SRPT: 23.04 (+0.75), TKMR: 19.82 (+0.55), NNVC: 3.44 (+0.04), GSK: 45.36 (+0.95)
CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financial Results
Business Wire - Fri Aug 08, 3:10PM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended June 30, 2014.
CVM: 0.69 (+0.02)
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.54 (unch), NWBO: 4.85 (+0.07), CVM: 0.69 (+0.02), CLDX: 15.41 (+0.90), INCY: 54.95 (+2.48), AZN: 69.35 (+0.57), MRK: 56.63 (+1.12), DNDN: 1.04 (+0.01), NLNK: 39.08 (-0.74), PPHM: 1.47 (+0.02), BMY: 52.50 (+0.66), FPRX: 12.09 (+0.09)
Cel-Sci's Enrollment Math Doesn't Add up
at The Street - Fri Aug 01, 10:11AM CDT
In order to enroll the remaining 648 patients into the Multikine study by the end of 2015, Cel-Sci needs to average 40.5 patients per month, or 121.5 patients per quarter.
CVM: 0.69 (+0.02)
Investors look to Lighten Up on Shares of CEL-SCI, Shares Down 20.6% (CVM)
Comtex SmarTrend(R) - Tue Oct 21, 10:13AM CDT
CEL-SCI (AMEX:CVM) is one of today's worst performing penny stocks, down 20.6% to $0.68 on 7.0x average daily volume. Thus far today, CEL-SCI has traded 2.0 million shares, vs. average volume of 285,000 shares per day. The stock has underperformed the Dow (-20.6% to the Dow's 0.6%) and underperformed the S&P 500 (-20.6% to the S&P's 1.2%) during today's trading.
CVM: 0.69 (+0.02)
CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering
Business Wire - Tue Oct 21, 8:42AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, has agreed to sell common stock and warrants in a registered direct offering to European investors at a combined price of $0.76 for aggregate gross proceeds of a little over $1 million. For every four shares sold, we will issue to investors in this offering one warrant to purchase a share of common stock. The warrants are immediately exercisable, expire October 11, 2018, have an exercise price of $1.25 and trade on the NYSE MKT under the symbol "CVM WS". The offering is expected to close on or about October 24, 2014, subject to the satisfaction of customary closing conditions.
CVM: 0.69 (+0.02)
CEL-SCI Corporation Prices $6 Million Public Offering of Common Stock and Warrants
Business Wire - Tue Oct 21, 8:15AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has priced a "best efforts" underwritten public offering of common stock and warrants at a combined price of $0.76 for aggregate gross proceeds of $6 million, prior to deducting underwriting commissions and offering expenses and excluding the exercise of any warrants. For every four shares sold, we will issue to investors in this offering one warrant to purchase a share of common stock. The warrants are immediately exercisable, expire October 11, 2018, have an exercise price of $1.25 and trade on the NYSE MKT under the symbol "CVM WS". The offering is expected to close on or about October 24, 2014, subject to the satisfaction of customary closing conditions.
CVM: 0.69 (+0.02)
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants
Business Wire - Mon Oct 20, 3:30PM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it intends to offer and sell common stock and warrants in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed.
CVM: 0.69 (+0.02)
Warts Therapeutics Pipeline Review 2014
M2 - Mon Oct 13, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wc94mt/warts_pipeline) has announced the addition of the "Warts - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Helix BioPharma Corp. - CEL-SCI Corporation - NanoViricides, Inc. - 3M Drug Delivery Systems - G&E Herbal Biotechnology Co., Ltd. - Anaconda Pharma - Foamix Ltd. - BioMAS Ltd. - ViroStatics, srl - Cutanea Life Sciences - Burke Pharmaceuticals, LLC - Agilvax, Inc. - Nielsen Biosciences, Inc. Drug Profiles - interferon alpha-2b (recombinant) - AS-101 - SRT-100 - AP-611074 - Candida Albicans Antigen - (digoxin furosemide) - Leukocyte Interleukin - A-101 - BURKE-201 - AX-03 - HerpeCide-I - imiquimod - 854-A - PP-210 - Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts For more information visit http://www.researchandmarkets.com/research/wc...s_pipeline
CVM: 0.69 (+0.02), NNVC: 3.44 (+0.04)
CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial
Business Wire - Fri Oct 03, 8:15AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of September the Company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection).
CVM: 0.69 (+0.02)
Coverage Initiation Report Focuses on CEL-SCI Corporation
Marketwire - Wed Oct 01, 10:33AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) is the subject of an in-depth initiation coverage report by Acceleron Equity Research.
CVM: 0.69 (+0.02)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Wed Oct 01, 6:00AM CDT
hen a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
CVM: 0.69 (+0.02), PLUG: 4.30 (+0.01), NYNY: 6.51 (+0.17), MERU: 3.94 (+0.01)
CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients
Business Wire - Mon Sep 29, 7:00AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced the first volunteer patient has been enrolled and administered Multikine* (Leukocyte Interleukin, Injection) in a Institutional Review Board approved Phase I Clinical Trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women at the Naval Medical Center San Diego (NMCSD). The purpose of this dose escalation study is to evaluate the safety and impact of Multikine as a treatment of Human Papilloma Virus associated peri-anal warts and assess the effect on anal intraepithelial dysplasia (AIN) in HIV/HPV co-infected men and women.
CVM: 0.69 (+0.02)
Hot Stock: CEL-SCI, Shares Drop 5.5% (CVM)
Comtex SmarTrend(R) - Tue Sep 23, 11:36AM CDT
CEL-SCI (AMEX:CVM) is one of today's worst performing penny stocks, down 5.5% to $0.81 on 1.1x average daily volume. CEL-SCI has traded 263,000 shares thus far today, vs. average volume of 234,000 shares per day. The stock has underperformed the Dow (-4.9% to the Dow's -0.3%) and underperformed the S&P 500 (-4.9% to the S&P's -0.3%) during today's trading.
CVM: 0.69 (+0.02)
Valuation Analysis for CEL-SCI
ACCESSWIRE - Thu Sep 11, 5:18AM CDT
Los Angeles, CA / September 11, 2014 / On Wednesday, CEL-SCI Corporation (NYSEMKT: CVM) made public the fact that the respected University of Minnesota's Masonic Cancer Center has become part of the company's Phase III head and neck cancer clinical trial. This is the 7th clinical site in the U.S. to join CEL-SCI's late stage study for its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection).
CVM: 0.69 (+0.02)
University of Minnesota Masonic Cancer Center Joins CEL-SCI's Phase III Head & Neck Cancer Trial
Business Wire - Wed Sep 10, 7:45AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that the University of Minnesota's Masonic Cancer Center has becomes the 7th clinical site in the U.S. to join its Phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection).
CVM: 0.69 (+0.02)
Smallpox Therapeutics Pipeline Review Report 2014 - 15 Companies & 16 Drug Profiles
M2 - Wed Sep 10, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdcds3/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - Conkwest, Inc. - Inhibikase Therapeutics, Inc. - Polyrizon Ltd. Drug Profiles - smallpox vaccine [Modified Vaccinia Ankara - Bavarian Nordic Virus] - CJ-50300 - brincidofovir - Sym-002 - cidofovir - CEL-1000 - tecovirimat - DNA Vaccine for Smallpox - Smallpox Vaccine - CST-102 - DNA Vaccine for Smallpox - TPIV-300 - imatinib mesylate - Monoclonal Antibody for Infectious Disease - PL-801 - Smallpox Vaccine For more information visit http://www.researchandmarkets.com/research/hdcds3/smallpox
MGNX: 19.69 (+0.41), CMRX: 32.06 (+1.45), CVM: 0.69 (+0.02), SIGA: 1.39 (-0.03)
CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial
Business Wire - Wed Sep 03, 7:01AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced that it enrolled 20 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) during August 2014. This brings the total study enrollment to 252 patients.
CVM: 0.69 (+0.02)
CEL-SCI Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial into Centre Hospitalier Universitaire de Quebec in Canada
Business Wire - Tue Aug 19, 7:01AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has added Centre Hospitalier Universitaire de Quebec (CHUQ)'s L'Hotel Dieu de Quebec to its growing number of clinical sites in North America. CHUQ is a network of three teaching hospitals affiliated with the medical school of Universite Laval and several specialized institutions in Quebec City. CEL-SCI plans to activate additional clinical sites for accelerated patient enrollment in Canada.
CVM: 0.69 (+0.02)
Potential Payoffs Spur Big Board Biotech Action
ACCESSWIRE - Tue Aug 12, 2:03PM CDT
Los Angeles, CA / ACCESSWIRE / August 12, 2014 / Speculators were pushing certain big board biotechs higher as they placed their bets on potentially big future payoffs.
BCRX: 12.19 (+0.49), CVM: 0.69 (+0.02), SRPT: 23.04 (+0.75), TKMR: 19.82 (+0.55), NNVC: 3.44 (+0.04), GSK: 45.36 (+0.95)
CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financial Results
Business Wire - Fri Aug 08, 3:10PM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended June 30, 2014.
CVM: 0.69 (+0.02)
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.54 (unch), NWBO: 4.85 (+0.07), CVM: 0.69 (+0.02), CLDX: 15.41 (+0.90), INCY: 54.95 (+2.48), AZN: 69.35 (+0.57), MRK: 56.63 (+1.12), DNDN: 1.04 (+0.01), NLNK: 39.08 (-0.74), PPHM: 1.47 (+0.02), BMY: 52.50 (+0.66), FPRX: 12.09 (+0.09)
Cel-Sci's Enrollment Math Doesn't Add up
at The Street - Fri Aug 01, 10:11AM CDT
In order to enroll the remaining 648 patients into the Multikine study by the end of 2015, Cel-Sci needs to average 40.5 patients per month, or 121.5 patients per quarter.
CVM: 0.69 (+0.02)
